Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity.

Kim MJ, Huang SM, Meyer UA, Rahman A, Lesko LJ.

J Clin Pharmacol. 2009 Feb;49(2):138-46. doi: 10.1177/0091270008328098. Review.

PMID:
19179293
2.

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.

Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, Anderson JL, Kimmel SE, Lee MT, Pirmohamed M, Wadelius M, Klein TE, Altman RB; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2011 Oct;90(4):625-9. doi: 10.1038/clpt.2011.185. Epub 2011 Sep 7. Review.

3.

Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin.

Flockhart DA, O'Kane D, Williams MS, Watson MS, Flockhart DA, Gage B, Gandolfi R, King R, Lyon E, Nussbaum R, O'Kane D, Schulman K, Veenstra D, Williams MS, Watson MS; ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use.

Genet Med. 2008 Feb;10(2):139-50. doi: 10.1097/GIM.0b013e318163c35f.

PMID:
18281922
4.

[Warfarin resistance and related pharmacogenetic information].

Takahashi H.

Brain Nerve. 2008 Nov;60(11):1365-71. Review. Japanese.

PMID:
19069171
5.

Role of warfarin pharmacogenetic testing in clinical practice.

Tan GM, Wu E, Lam YY, Yan BP.

Pharmacogenomics. 2010 Mar;11(3):439-48. doi: 10.2217/pgs.10.8. Review.

PMID:
20402581
6.

[Application of warfarin pharmacogenetics].

Tomek A, Mat'oska V, Kumstýrfová T, Táborský L.

Vnitr Lek. 2009 Jun;55(6):565-9. Review. Czech.

PMID:
19662888
7.

Pathology consultation on warfarin pharmacogenetic testing.

Stack G; Education Committee of the Academy of Clinical Laboratory Physicians and Scientists.

Am J Clin Pathol. 2011 Jan;135(1):13-9. doi: 10.1309/AJCPAO82OTNPUBLW. No abstract available.

PMID:
21173120
8.

Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.

You JH, Tsui KK, Wong RS, Cheng G.

Clin Pharmacol Ther. 2009 Nov;86(5):540-7. doi: 10.1038/clpt.2009.104. Epub 2009 Jul 1.

PMID:
19571807
9.

Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.

Kim HS, Lee SS, Oh M, Jang YJ, Kim EY, Han IY, Cho KH, Shin JG.

Pharmacogenet Genomics. 2009 Feb;19(2):103-12. doi: 10.1097/FPC.0b013e32831a9ae3.

PMID:
19077919
10.

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.

Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F.

Blood. 2005 Oct 1;106(7):2329-33. Epub 2005 Jun 9.

11.

Pharmacogenomic testing for warfarin dosing: we are ready now.

Wu AH.

Expert Rev Cardiovasc Ther. 2009 Dec;7(12):1483-5. doi: 10.1586/erc.09.117. No abstract available.

PMID:
19954308
12.

CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.

Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ.

Pharmacogenomics. 2009 Aug;10(8):1243-55. doi: 10.2217/pgs.09.71.

13.

An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.

Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL.

Thromb Haemost. 2008 Aug;100(2):229-39.

PMID:
18690342
14.

Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.

Moyer TP, O'Kane DJ, Baudhuin LM, Wiley CL, Fortini A, Fisher PK, Dupras DM, Chaudhry R, Thapa P, Zinsmeister AR, Heit JA.

Mayo Clin Proc. 2009 Dec;84(12):1079-94. doi: 10.4065/mcp.2009.0278. Review.

15.

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.

Eckman MH, Rosand J, Greenberg SM, Gage BF.

Ann Intern Med. 2009 Jan 20;150(2):73-83.

PMID:
19153410
16.

Genetic testing for warfarin dosing? Not yet ready for prime time.

Bussey HI, Wittkowsky AK, Hylek EM, Walker MB.

Pharmacotherapy. 2008 Feb;28(2):141-3. doi: 10.1592/phco.28.2.141. No abstract available.

PMID:
18225960
17.

Should we be applying warfarin pharmacogenetics to clinical practice? No, not now.

Rosove MH, Grody WW.

Ann Intern Med. 2009 Aug 18;151(4):270-3, W95.

PMID:
19687493
18.

A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding.

McClain MR, Palomaki GE, Piper M, Haddow JE.

Genet Med. 2008 Feb;10(2):89-98. doi: 10.1097/GIM.0b013e31815bf924. Review.

PMID:
18281915
19.

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.

Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL.

Clin Pharmacol Ther. 2008 Sep;84(3):326-31. doi: 10.1038/clpt.2008.10. Epub 2008 Feb 27. Erratum in: Clin Pharmacol Ther. 2008 Sep;84(3):430.

20.

Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.

Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, Novelli G.

Pharmacogenomics. 2007 Nov;8(11):1545-50.

PMID:
18034619

Supplemental Content

Support Center